

**Wisconsin Society of Addiction Medicine
MONTHLY TELECONFERENCE
Thursday, June 28, 2018**



Moderator: Matthew Felgus, MD, FASAM
WISAM President

Attendees: Matthew Felgus, MD; Alek Zgierska, MD (WISAM Immediate Past-President); Ritu Bhatnagar, Dan Sessler, John Joseph, Cathy Oriold.

Welcome

The meeting was called to order at 7pm.

WISAM Updates

- Annual Conference. Save the Date September 27-29, 2018, Pyle Center, Madison Wisconsin.
- Webinar – Treatment of Substance Use Disorders in Primary Care. Dr. Bhatnagar provided an update on the first webinar presented on 6/20. We encourage advanced registration but it's still possible to view prior webinars with free registration:

Overview: This complimentary four-part webinar series, funded in part through a Wisconsin Medical Society Foundation grant, provides timely information and updates related to the treatment of substance use disorders. All presenters are local experts who have a clear understanding of Wisconsin's rural issues and barriers to care.

Target audience: Primary care providers in rural areas of Wisconsin who receive little support and education for evidence-based treatment of substance use disorders. Anyone may participate.

Participation: Registration is open and additional details are online at www.WISAM-ASAM.org/webinars Participants may attend the webinars in-person at Meriter Hospital in Madison on the date/time indicated OR through the on-demand webinar option, which will be available free of charge approximately 1 week after the webinar for up to one year following the recording.

Part 1: Wednesday, June 20, 2018, 5:30-6:30 pm
Suboxone 2.0: Beyond the Basics; Presented by Ritu Bhatnagar, MD

Part 2: Wednesday, July 18, 2018; 5:30-6:30 pm
Interpretation of Urine Drug Screen; Presented by David Galbis-Reig, MD

Part 3: Wednesday, August 15, 2018, 5:30-6:30 pm Treatment of Stimulant Disorder;
Presented by Mark Lim, MD

Part 4: Wednesday, October 17, 2018; 5:30-6:30 pm
Treatment of Alcohol Use and Opioid Use Disorder in Pregnancy; Presented by
Jacquelyn Adams, MD

- Pew Charitable Trust: On 6/20, a meeting was held by the Pew group to discuss the results of the focus groups held several months ago. The purpose of the focus groups was to examine the experiences of individuals in accessing treatment for OUD. Specifically, information was provided around better understanding barriers to treatment access with the goal to develop policy options leading to policy change. For those interested in the specifics of the meeting, email WISAM and we will attempt to provide the slide set used for this meeting.

- Clinical issues:
 - Discussion of safety of naloxone/naltrexone in breast-feeding mothers. Although the standard of care is to switch pregnant patients from buprenorphine-naloxone compounds to sole buprenorphine, there is not strong evidence of any harm to the unborn baby of naloxone.
 - IM Naltrexone (Vivitrol) is a Category C medication. Regarding breast-feeding, there is minimal passage of naltrexone into breast milk. Benefits need to exceed any risks to the baby. Breast feeding is still preferable to formula even in women on IM naltrexone although there was some discussion regarding this. There is not a large population of breast-feeding women on IM naltrexone to study. Dr Zgierska reached out to an OB following the meeting for his input and further resources.
 - There was a discussion of treatment of patients with buprenorphine and benzodiazepines. Opinions ranged from refusal to start buprenorphine without tapering the benzodiazepine to a more measured tapering, especially in patients that one inherits from other MDs who are already on this combination. Several of the participants have patients on this combination of medications in treatment. All agreed that the eventual goal should be discontinuation of the benzodiazepine but this may happen very slowly if at all in some patients.
 - Non-benzodiazepine medication options for anxiety were also discussed.

Adjourn

The meeting adjourned at 8:03 pm. Next teleconference meetings: Thursday, October 25, 2018.